Home/Pipeline/Enhanced Seasonal Influenza Vaccine

Enhanced Seasonal Influenza Vaccine

Influenza

ResearchActive

Key Facts

Indication

Influenza

Phase

Research

Status

Active

Company

Orlance

About Orlance

Orlance is advancing the MACH-1 platform, a needle-free gene gun technology that delivers powdered DNA or RNA vaccines directly into the epidermis, aiming to reduce doses by up to 90% and eliminate cold chain requirements. The company has secured significant non-dilutive funding, primarily from NIH SBIR grants totaling over $16.8M, to progress its pipeline toward Phase 1 trials. With a lead universal flu vaccine at the pre-IND stage, Orlance is preparing for a $12M Series A round in 2026 and is actively seeking development partners to expand its portfolio of vaccine and immunotherapy assets.

View full company profile

Therapeutic Areas

Infectious Disease Oncology

Other Influenza Drugs

Drug	Company	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	IND Submitted	Active
Mimotopes-004	Mimotopes	Preclinical	Active
Next-Gen / Universal Flu Vaccines	CSL Seqirus	Research / Early Clinical	Active
Oseltamivir 75 mg	MSN Laboratories	Commercial	Active
AI Programme - Influenza	Poolbeg Pharma	Discovery	Active - Target/Candidate ID
Influenza Antibodies	new/era/mabs	Research/Pre-clinical	Active
Influenza Countermeasure Program	DynPort Vaccines	Not Specified	Active
Influenza Vaccine	Medigen	Preclinical	Active
Nasal Influenza Vaccine	Abera Bioscience	Pre-clinical	Active
Zapnometinib (ATR-002)	Atriva Therapeutics	Phase 2	Active
EV25	Eradivir	Pre-clinical	Active
Not Specified	New Amsterdam Sciences	Pre-clinical	Active